Literature DB >> 33236525

International consensus statement on allergy and rhinology: rhinosinusitis 2021.

Richard R Orlandi1, Todd T Kingdom2, Timothy L Smith3, Benjamin Bleier4, Adam DeConde5, Amber U Luong6, David M Poetker7, Zachary Soler8, Kevin C Welch9, Sarah K Wise10, Nithin Adappa11, Jeremiah A Alt1, Wilma Terezinha Anselmo-Lima12, Claus Bachert13,14,15, Fuad M Baroody16, Pete S Batra17, Manuel Bernal-Sprekelsen18, Daniel Beswick19, Neil Bhattacharyya4, Rakesh K Chandra20, Eugene H Chang21, Alexander Chiu22, Naweed Chowdhury23, Martin J Citardi6, Noam A Cohen11, David B Conley24, John DelGaudio10, Martin Desrosiers25, Richard Douglas26, Jean Anderson Eloy27, Wytske J Fokkens28, Stacey T Gray4, David A Gudis29, Daniel L Hamilos30, Joseph K Han31, Richard Harvey32, Peter Hellings33, Eric H Holbrook4, Claire Hopkins34, Peter Hwang35, Amin R Javer36, Rong-San Jiang37, David Kennedy11, Robert Kern24, Tanya Laidlaw4, Devyani Lal38, Andrew Lane39, Heung-Man Lee40, Jivianne T Lee19, Joshua M Levy10, Sandra Y Lin39, Valerie Lund41, Kevin C McMains42, Ralph Metson4, Joaquim Mullol43, Robert Naclerio39, Gretchen Oakley1, Nobuyoshi Otori44, James N Palmer11, Sanjay R Parikh45, Desiderio Passali46, Zara Patel35, Anju Peters24, Carl Philpott47, Alkis J Psaltis48, Vijay R Ramakrishnan2, Murugappan Ramanathan39, Hwan-Jung Roh49, Luke Rudmik50, Raymond Sacks51, Rodney J Schlosser8, Ahmad R Sedaghat52, Brent A Senior53, Raj Sindwani54, Kristine Smith55, Kornkiat Snidvongs56, Michael Stewart57, Jeffrey D Suh19, Bruce K Tan24, Justin H Turner23, Cornelis M van Drunen58, Richard Voegels59, De Yun Wang60, Bradford A Woodworth61, Peter-John Wormald48, Erin D Wright62, Carol Yan63, Luo Zhang64, Bing Zhou64.   

Abstract

I. EXECUTIVE
SUMMARY:
BACKGROUND: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR-RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR-RS-2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence-based findings of the document.
METHODS: ICAR-RS presents over 180 topics in the forms of evidence-based reviews with recommendations (EBRRs), evidence-based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary.
RESULTS: ICAR-RS-2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence-based management algorithm is provided.
CONCLUSION: This ICAR-RS-2021 executive summary provides a compilation of the evidence-based recommendations for medical and surgical treatment of the most common forms of RS.
© 2021 ARS-AAOA, LLC.

Entities:  

Keywords:  acute rhinosinusitis; chronic rhinosinusitis; endoscopic sinus surgery; evidence-based medicine; recurrent acute rhinosinusitis; rhinosinusitis; systematic review

Mesh:

Year:  2021        PMID: 33236525     DOI: 10.1002/alr.22741

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   5.426


  40 in total

1.  [Postoperative treatment following paranasal sinus surgery].

Authors:  Thomas S Kühnel; Werner G Hosemann; Rainer Weber
Journal:  HNO       Date:  2021-05-03       Impact factor: 1.284

2.  Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis.

Authors:  Lauren T Roland; Sarah K Wise; Heqiong Wang; Christina Mehta; John M DelGaudio; Joshua M Levy
Journal:  Int Forum Allergy Rhinol       Date:  2021-10-01       Impact factor: 3.858

Review 3.  Comparison of guidelines for prescription and follow-up of biologics for chronic rhinosinusitis with nasal polyps.

Authors:  Andrea Rampi; Alessandro Vinciguerra; Umberto Tanzini; Mario Bussi; Matteo Trimarchi
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-13       Impact factor: 3.236

4.  Cystatin SN is a potent upstream initiator of epithelial-derived type 2 inflammation in chronic rhinosinusitis.

Authors:  Angela L Nocera; Sarina K Mueller; Alan D Workman; Dawei Wu; Kristen McDonnell; Peter M Sadow; Mansoor M Amiji; Benjamin S Bleier
Journal:  J Allergy Clin Immunol       Date:  2022-05-31       Impact factor: 14.290

5.  SARS-CoV-2 infection and the human immune system: A continuing journey of discovery.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-11-01       Impact factor: 2.587

6.  Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis.

Authors:  Gayatri B Patel; Elizabeth A Kudlaty; Amina Guo; Chen Yeh; Margaret S Kim; Caroline P E Price; David Conley; Leslie C Grammer; Ravi Kalhan; Robert C Kern; Kris G McGrath; Bruce K Tan; Sharon R Rosenberg; Robert P Schleimer; Stephanie S Smith; Whitney W Stevens; Kevin C Welch; Anju T Peters
Journal:  Allergy Asthma Proc       Date:  2021-09-01       Impact factor: 2.587

Review 7.  Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.

Authors:  Atsushi Kato; Anju T Peters; Whitney W Stevens; Robert P Schleimer; Bruce K Tan; Robert C Kern
Journal:  Allergy       Date:  2021-09-15       Impact factor: 14.710

8.  Long-Term Exposure to Particulate Matter Air Pollution and Chronic Rhinosinusitis in Nonallergic Patients.

Authors:  Zhenyu Zhang; Rebecca J Kamil; Nyall R London; Stella E Lee; Venkataramana K Sidhaye; Shyam Biswal; Andrew P Lane; Jayant M Pinto; Murugappan Ramanathan
Journal:  Am J Respir Crit Care Med       Date:  2021-10-01       Impact factor: 30.528

Review 9.  Management of Chronic Rhinosinusitis with Nasal Polyposis in the Era of Biologics.

Authors:  Justin C Morse; Craig Miller; Brent Senior
Journal:  J Asthma Allergy       Date:  2021-07-12

Review 10.  Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.

Authors:  Ryan Eid; Carol H Yan; Whitney Stevens; Taylor A Doherty; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2021-08       Impact factor: 14.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.